US Generic Drug Market Size, Share, Outlook, Industry Trends and Forecast 2022-2027

According to IMARC Group's latest report, titled "𝗨𝗦 𝗚𝗲𝗻𝗲𝗿𝗶𝗰 𝗗𝗿𝘂𝗴 𝗠𝗮𝗿𝗸𝗲𝘁: 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗧𝗿𝗲𝗻𝗱𝘀, 𝗦𝗵𝗮𝗿𝗲, 𝗦𝗶𝘇𝗲, 𝗚𝗿𝗼𝘄𝘁𝗵, 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝗮𝗻𝗱 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁 𝟮𝟬𝟮𝟮-𝟮𝟬𝟮𝟳", the US generic drug market size reached US$ 83.2 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 105.7 Billion by 2027, exhibiting a CAGR of 3.9% during 2022-2027.

𝗬𝗲𝗮𝗿 𝗖𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗲𝗱 𝘁𝗼 𝗘𝘀𝘁𝗶𝗺𝗮𝘁𝗲 𝘁𝗵𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗶𝘇𝗲:

Base Year of the Analysis: 2021

Historical Period: 2016-2021

Forecast Period: 2022-2027

𝗨𝗦 𝗚𝗲𝗻𝗲𝗿𝗶𝗰 𝗗𝗿𝘂𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝗢𝘃𝗲𝗿𝘃𝗶𝗲𝘄:

Generic drugs are off-patent, non-branded medications that act as bioequivalent to their branded counterparts and contain similar active ingredients. In terms of their strength, purity, and quality, they are able to meet the batch-to-batch requirements as the original manufactured products. They are further identical in dose, route of administration, safety, functionality, intended usage, and yielding the same therapeutic effect. Apart from this, generic drugs are more inexpensive than authentic products since they do not require extensive research and development (R&D) procedures to formulate drugs from scratch or spend money on advertising and marketing. Consequently, generic drugs are introduced and marketed after a patent expires or if the original producer waives its rights.

𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗳𝗿𝗲𝗲 𝘀𝗮𝗺𝗽𝗹𝗲 𝗯𝗿𝗼𝗰𝗵𝘂𝗿𝗲: https://www.imarcgroup.com/us-generics-market/requestsample

𝗨𝗦 𝗚𝗲𝗻𝗲𝗿𝗶𝗰 𝗗𝗿𝘂𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝐓𝐫𝐞𝐧𝐝𝐬

The increasing need for cost-effective medications to treat various cardiovascular diseases is primarily driving the market growth. Furthermore, the ongoing generic drug approvals facilitated by the implementation of the Drug Competition Action Plan by the food and drug administration (FDA), aiming to eliminate hurdles faced by generic-drug manufacturers and improve their development and approval, are favoring the market growth. Moreover, the widespread adoption of several schemes to incentivize physicians and pharmacists to encourage generic substitution and the growing consumer awareness regarding the availability of low-cost-treatment options are impelling the market growth. Besides this, the rising usage of artificial intelligence (AI) technology and robotic process automation (RPA) to automate generic drug production at the minimized time, energy, and capital while complying with rules-based procedures to meet regulatory standards is supporting the market growth.

𝗖𝗵𝗲𝗰𝗸𝗼𝘂𝘁 𝗡𝗼𝘄: https://www.imarcgroup.com/checkout?id=567&method=1

𝗨𝗦 𝗚𝗲𝗻𝗲𝗿𝗶𝗰 𝗗𝗿𝘂𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟮-𝟮𝟬𝟮𝟳 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗮𝗻𝗱 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻:

𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗪𝗶𝘁𝗵 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀:

The competitive landscape of the US generic drug market has been studied in the report with the detailed profiles of the key players operating in the market.

𝗦𝗼𝗺𝗲 𝗼𝗳 𝘁𝗵𝗲𝘀𝗲 𝗸𝗲𝘆 𝗽𝗹𝗮𝘆𝗲𝗿𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗲:

• Teva
• Mylan
• Actavis (Teva)
• Sandoz (Novartis)
• Sun Pharma
• Par Pharmaceuticals (Endo Pharmaceuticals)
• Lupin Pharmaceuticals
• Dr Reddy's
• Hospira (Pfizer)

𝗞𝗲𝘆 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻:

The report has segmented the US generic drug market on the basis of segment, therapy area, drug delivery and distribution channel.

𝗕𝗿𝗲𝗮𝗸𝘂𝗽 𝗯𝘆 𝗦𝗲𝗴𝗺𝗲𝗻𝘁:

• Unbranded
• Branded

𝗕𝗿𝗲𝗮𝗸𝘂𝗽 𝗯𝘆 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗔𝗿𝗲𝗮:

• CNS
• Cardiovascular
• Dermatology
• Genitourinary/Hormonal
• Respiratory
• Rheumatology
• Diabetes
• Oncology
• Others

𝗕𝗿𝗲𝗮𝗸𝘂𝗽 𝗯𝘆 𝗗𝗿𝘂𝗴 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆:

• Oral
• Injectables
• Dermal/Topical
• Inhalers

𝗕𝗿𝗲𝗮𝗸𝘂𝗽 𝗯𝘆 𝗗𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻 𝗖𝗵𝗮𝗻𝗻𝗲𝗹:

• Hospital Pharmacies
• Retail Pharmacies

𝗔𝘀𝗸 𝗔𝗻𝗮𝗹𝘆𝘀𝘁 𝗳𝗼𝗿 𝟭𝟬% 𝗳𝗿𝗲𝗲 𝗰𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗲𝗱 𝗿𝗲𝗽𝗼𝗿𝘁: https://www.imarcgroup.com/request?type=report&id=567&flag=C

𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗥𝗲𝗽𝗼𝗿𝘁:

• Market Performance (2016-2021)
• Market Outlook (2022-2027)
• Market Trends
• Market Drivers and Success Factors
• Impact of COVID-19
• Value Chain Analysis
• Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗨𝗦:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Website: https://www.imarcgroup.com/
Email: sales@imarcgroup.com
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800

This release was published on openPR.